Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease.


Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 20 06 2021
revised: 08 10 2021
accepted: 17 10 2021
pubmed: 11 11 2021
medline: 19 1 2022
entrez: 10 11 2021
Statut: ppublish

Résumé

To alleviate the overflow of coronavirus disease 2019 (COVID-19) patients in hospitals, less invasive and simple criteria are required to triage the patients. We evaluated the relationship between COVID-19 severity and fatty liver on plain computed tomography (CT) scan performed on admission. In this retrospective cohort study, we considered all COVID-19 patients at a large tertiary care hospital between January 31 and August 31, 2020. COVID-19 severity was categorized into severe (moderate and severe) and non-severe (asymptomatic and mild) groups, based on the Japanese National COVID-19 guidelines. Fatty liver was detected on plain CT scan. Multivariate logistic regression analysis was performed to evaluate factors associated with severe COVID-19. Of 222 patients (median age: 52 years), 3.2%, 58.1%, 20.7%, and 18.0% presented with asymptomatic, mild, moderate, and severe COVID-19, respectively. Although 59.9% had no fatty liver on plain CT, mild, moderate, and severe fatty liver occurred in 13.1%, 18.9%, and 8.1%, respectively. Age and presence of fatty liver were significantly associated with severe COVID-19. Our study showed that fatty liver on plain CT scan on admission can become a risk factor for severe COVID-19. This finding may help clinicians to easily triage COVID-19 patients.

Identifiants

pubmed: 34756574
pii: S1341-321X(21)00282-8
doi: 10.1016/j.jiac.2021.10.013
pmc: PMC8526433
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

217-223

Informations de copyright

Copyright © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Ayako Okuhama (A)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Masatoshi Hotta (M)

Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.

Masahiro Ishikane (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ishikanemasahiro@gmail.com.

Akira Kawashima (A)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yusuke Miyazato (Y)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Mari Terada (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.

Gen Yamada (G)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Kohei Kanda (K)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Makoto Inada (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Lubna Sato (L)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Mitsuhiro Sato (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yutaro Akiyama (Y)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Tetsuya Suzuki (T)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Takato Nakamoto (T)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Hidetoshi Nomoto (H)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Satoshi Ide (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Keiji Nakamura (K)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Sho Saito (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Noriko Kinoshita (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Kei Yamamoto (K)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Shinichiro Morioka (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Mugen Ujiie (M)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Kayoko Hayakawa (K)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Satoshi Kustuna (S)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yoshitaka Shida (Y)

Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.

Tsuyoshi Tajima (T)

Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan.

Katsuji Teruya (K)

AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan.

Yumi Funato (Y)

Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan.

Makiko Yamamoto (M)

Department of Emergency Medicine and Critical Care, National Center for Global Health and Medicine, Tokyo, Japan.

Shinyu Izumi (S)

Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.

Masayuki Hojo (M)

Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.

Haruhito Sugiyama (H)

National Center for Global Health and Medicine, Tokyo, Japan.

Norio Ohmagari (N)

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH